Welcome to LookChem.com Sign In|Join Free

CAS

  • or

250641-14-6

Post Buying Request

250641-14-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

250641-14-6 Usage

General Description

6-Bromoquinoline-2,4-dicarboxylic acid is a chemical compound with the molecular formula C11H6BrNO4. It is a derivative of quinoline and contains two carboxylic acid functional groups. 6-BroMoquinoline-2,4-dicarboxylic acid is often used in organic synthesis and pharmaceutical research due to its potential biological activity and ability to modulate protein-protein interactions. It has been studied for its potential use in drug discovery, particularly in the development of novel anti-cancer or anti-inflammatory agents. Additionally, 6-Bromoquinoline-2,4-dicarboxylic acid has also been investigated for its potential as a building block in the synthesis of various organic compounds.

Check Digit Verification of cas no

The CAS Registry Mumber 250641-14-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,0,6,4 and 1 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 250641-14:
(8*2)+(7*5)+(6*0)+(5*6)+(4*4)+(3*1)+(2*1)+(1*4)=106
106 % 10 = 6
So 250641-14-6 is a valid CAS Registry Number.

250641-14-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name 6-Bromoquinoline-2,4-dicarboxylic acid

1.2 Other means of identification

Product number -
Other names 6-bromo-quinoline-2,4-dicarboxylic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:250641-14-6 SDS

250641-14-6Relevant articles and documents

-

Buchman et al.

, p. 2692,2693 (1946)

-

Inhibitor-conjugated harmonic nanoparticles targeting fibroblast activation protein

De Matos, Rapha?l,Vuilleumier, Jérémy,Mas, Christophe,Constant, Samuel,Staedler, Davide,Gerber-Lemaire, Sandrine

, p. 31659 - 31669 (2019/10/19)

The recent progress in the engineering of nanosized inorganic materials presenting tailored physical properties and reactive surface for post-functionalization has opened promising avenues for the use of nanoparticles (NPs) in diagnosis and therapeutic intervention. Surface decoration of metal oxide NPs with ligands modulating circulation time, cellular uptake, affinity and extravasation through active targeting led to efficient cancer specific bioimaging probes. The most relevant cancer biomarkers studied so far include surface and transmembrane cancer cell receptors. More recently, tumor microenvironments and more specifically the fibroblastic element of the tumor stroma have emerged as a valuable target for diagnosis and treatment of several types of cancers. In this study, a low molecular weight ligand targeting fibroblast activation protein α (FAP), which is specifically expressed by activated fibroblasts of the tumor stroma, was synthesized. This ligand demonstrated nanomolar inhibition of FAP with high selectivity with respect to prolyl oligopeptidase (PREP) and dipeptidyl peptidase (DPP) IV, as well as good biocompatibility toward a human lung tissue model. Bismuth ferrite (BFO) harmonic nanoparticles (HNPs) conjugated to this ligand showed target-specific association to FAP as demonstrated by reverse ELISA-type assay using Human Fibroblast Activation Protein alpha/FAP Alexa Fluor 594-conjugated Antibody and multiphoton multispectral microscopy experiments. These functionalized HNPs may provide new nanocarriers to explore the role of FAP in tumorigenesis and to target the fibroblastic component of the tumor microenvironment.

GLUCOSE TRANSPORT INHIBITORS

-

Page/Page column 129; 130, (2015/07/07)

The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 250641-14-6